Myocarditis following COVID-19 mRNA vaccinations: Twin and sibling case series.
Adverse Events of Special Interest
COVID-19 vaccination
Myocarditis
Vaccine safety
Journal
Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
02
03
2023
revised:
23
05
2023
accepted:
06
07
2023
medline:
24
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
ImportanceMyocarditis and myopericarditis are well described adverse events of special interest (AESI) following COVID-19 vaccinations. Whilst the aetiology is still being investigated; there is evidence that genetic predisposition may be a risk factor for the development of myocarditis. Furthermore, hormones are thought to contribute to sex-specific differences in myocarditis, skewed toward a larger risk in adolescent males. This unique sibling case series may help highlight potential mechanisms and prognostic factors in the development of myocarditis following COVID-19 vaccination in adolescent males. In this context, twin and familial studies provide a unique epidemiological perspective to investigate the interplay between genetic predisposition and other factors. Observational case series of all siblings reported to SAEFVIC with chest pain following COVID-19 vaccinations in Victoria, Australia. mRNA vaccination (Comirnaty BNT162b2 COVID-19 (Pfizer-BioNTech) and Spikevax mRNA-1273 (Moderna). Our case series comprises 6 young males; two sets of monozygotic twins and one set of fraternal brothers following reports of chest pain associated with COVID-19 mRNA vaccination. Five patients were diagnosed with myocarditis as per Brighton Collaboration Criteria (Level 2). The remaining sibling, who did not have myocarditis, was subsequently diagnosed with pubertal delay. Understanding the genetic and hormonal risk factors and aetiology for myocarditis associated with COVID-19 vaccines is paramount. Further evaluation of specific genetic targets or biomarkers is required to understand the implications of population vaccine policy, particularly for adolescent and young adult males at highest risk for this AESI.
Identifiants
pubmed: 37484868
doi: 10.1016/j.jvacx.2023.100350
pii: S2590-1362(23)00091-8
pmc: PMC10362306
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100350Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
JAMA. 2022 Jan 25;327(4):331-340
pubmed: 35076665
Vaccine. 2022 Mar 1;40(10):1499-1511
pubmed: 35105494
ESC Heart Fail. 2020 Jun;7(3):1210-1216
pubmed: 32301586
Vaccines (Basel). 2022 Apr 14;10(4):
pubmed: 35455360
J Am Heart Assoc. 2021 Sep 21;10(18):e021987
pubmed: 34533054
Asian J Androl. 2021 Jul-Aug;23(4):348-356
pubmed: 33433530
N Engl J Med. 2022 Oct 20;387(16):1524-1527
pubmed: 36130012
BMJ. 2021 Jun 14;373:n1435
pubmed: 35727911
Nat Rev Cardiol. 2022 Feb;19(2):75-77
pubmed: 34887571
Hum Mutat. 2018 Dec;39(12):2083-2096
pubmed: 30260051
J Am Coll Cardiol. 2016 Nov 29;68(21):2348-2364
pubmed: 27884253
J Pediatr. 2017 Jul;186:172-178.e3
pubmed: 28438374